4,699 Shares in LeMaitre Vascular, Inc. $LMAT Acquired by Evergreen Capital Management LLC

Evergreen Capital Management LLC bought a new position in shares of LeMaitre Vascular, Inc. (NASDAQ:LMAT) during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 4,699 shares of the medical instruments supplier’s stock, valued at approximately $381,000.

Other large investors have also recently made changes to their positions in the company. Cornerstone Planning Group LLC increased its stake in shares of LeMaitre Vascular by 534.0% during the third quarter. Cornerstone Planning Group LLC now owns 336 shares of the medical instruments supplier’s stock worth $30,000 after buying an additional 283 shares during the period. MAI Capital Management purchased a new position in LeMaitre Vascular in the third quarter valued at approximately $38,000. First Horizon Corp purchased a new position in LeMaitre Vascular in the third quarter valued at approximately $39,000. Geneos Wealth Management Inc. increased its stake in LeMaitre Vascular by 250.3% in the first quarter. Geneos Wealth Management Inc. now owns 557 shares of the medical instruments supplier’s stock valued at $47,000 after purchasing an additional 398 shares during the last quarter. Finally, EverSource Wealth Advisors LLC purchased a new position in LeMaitre Vascular in the second quarter valued at approximately $47,000. 84.64% of the stock is currently owned by hedge funds and other institutional investors.

LeMaitre Vascular Stock Performance

Shares of LeMaitre Vascular stock opened at $114.52 on Tuesday. The company has a quick ratio of 10.95, a current ratio of 12.89 and a debt-to-equity ratio of 0.43. The firm has a market capitalization of $2.62 billion, a P/E ratio of 45.63, a P/E/G ratio of 3.27 and a beta of 0.67. The firm’s 50 day moving average is $107.75 and its two-hundred day moving average is $93.50. LeMaitre Vascular, Inc. has a 52 week low of $78.01 and a 52 week high of $118.01.

LeMaitre Vascular (NASDAQ:LMAT) last announced its earnings results on Wednesday, February 25th. The medical instruments supplier reported $0.68 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.67 by $0.01. The business had revenue of $64.45 million for the quarter, compared to analyst estimates of $62.98 million. LeMaitre Vascular had a net margin of 23.13% and a return on equity of 14.72%. The company’s revenue for the quarter was up 15.7% compared to the same quarter last year. During the same period last year, the firm posted $0.49 earnings per share. LeMaitre Vascular has set its FY 2026 guidance at 2.810-3.010 EPS and its Q1 2026 guidance at 0.640-0.690 EPS. Research analysts forecast that LeMaitre Vascular, Inc. will post 2.89 EPS for the current fiscal year.

LeMaitre Vascular Increases Dividend

The firm also recently announced a quarterly dividend, which was paid on Thursday, March 26th. Stockholders of record on Thursday, March 12th were given a dividend of $0.25 per share. This represents a $1.00 dividend on an annualized basis and a dividend yield of 0.9%. This is a boost from LeMaitre Vascular’s previous quarterly dividend of $0.20. The ex-dividend date was Thursday, March 12th. LeMaitre Vascular’s payout ratio is 39.84%.

Wall Street Analyst Weigh In

Several equities analysts have commented on LMAT shares. Wall Street Zen upgraded shares of LeMaitre Vascular from a “hold” rating to a “buy” rating in a research note on Saturday, February 21st. Roth Mkm reiterated a “buy” rating and issued a $117.00 price target (up from $108.00) on shares of LeMaitre Vascular in a research note on Thursday, February 26th. Wells Fargo & Company increased their price target on shares of LeMaitre Vascular from $87.00 to $94.00 and gave the company an “equal weight” rating in a research note on Thursday, February 26th. Zacks Research upgraded shares of LeMaitre Vascular from a “hold” rating to a “strong-buy” rating in a research note on Monday, April 13th. Finally, Barrington Research increased their price target on shares of LeMaitre Vascular from $95.00 to $105.00 and gave the company an “outperform” rating in a research note on Thursday, February 26th. One research analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating and three have assigned a Hold rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $105.80.

Insider Transactions at LeMaitre Vascular

In other news, Director David B. Roberts sold 8,464 shares of the firm’s stock in a transaction that occurred on Friday, February 27th. The shares were sold at an average price of $106.80, for a total transaction of $903,955.20. Following the transaction, the director directly owned 17,979 shares in the company, valued at approximately $1,920,157.20. This trade represents a 32.01% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, insider Trent G. Kamke sold 1,044 shares of the firm’s stock in a transaction that occurred on Friday, February 27th. The stock was sold at an average price of $110.29, for a total transaction of $115,142.76. Following the transaction, the insider owned 6,677 shares in the company, valued at approximately $736,406.33. This trade represents a 13.52% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last ninety days, insiders have sold 215,438 shares of company stock worth $23,062,911. Insiders own 9.50% of the company’s stock.

LeMaitre Vascular Profile

LeMaitre Vascular, Inc is a specialty medical device company focused on the development, manufacture and marketing of products for the treatment of peripheral vascular disease. Headquartered in Burlington, Massachusetts, the company’s offerings include a broad portfolio of vascular surgical instruments, grafts, patches, catheters and embolic protection devices. LeMaitre’s product lines address key areas such as arterial reconstruction, endovascular repair and vascular access, serving the needs of cardiovascular surgeons and interventional specialists.

Founded in 1983 by George D.